Sign in or create an account to add this stock to your watchlist.
About ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio1.76
Current Ratio4.92
Quick Ratio5.35
Price-To-Earnings
Trailing P/E Ratio-2.85
Forward P/E Ratio-3.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales10.83
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book10.67
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-101.93%
Return on Equity-88.31%
Return on Assets-25.76%
Miscellaneous
Employees295
Outstanding Shares45,320,000
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings results on Monday, March, 5th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.27. The biotechnology company earned $12 million during the quarter, compared to the consensus estimate of $6.68 million. ADMA Biologics had a negative net margin of 101.93% and a negative return on equity of 88.31%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
2 analysts have issued 1 year target prices for ADMA Biologics' stock. Their predictions range from $5.00 to $10.00. On average, they expect ADMA Biologics' stock price to reach $7.50 in the next year. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Solid Biosciences (SLDB), Heska (HSKA), Novavax (NVAX), CASI Pharmaceuticals (CASI), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Vericel (VCEL), Mesoblast (MESO), Idera Pharmaceuticals (IDRA), Surface Oncology (SURF), PDL Biopharma (PDLI) and Nightstar Therapeutics (NITE).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Has ADMA Biologics been receiving favorable news coverage?
Media stories about ADMA stock have been trending somewhat positive on Monday, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a media sentiment score of 0.06 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.60%), BlackRock Inc. (0.09%), JPMorgan Chase & Co. (0.09%), Element Capital Management LLC (0.06%) and Spark Investment Management LLC (0.05%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman and James Mond. View Institutional Ownership Trends for ADMA Biologics.
Which major investors are buying ADMA Biologics stock?
ADMA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Element Capital Management LLC, Spark Investment Management LLC and BlackRock Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman and James Mond. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $5.44.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $246.52 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (ADMA)
| Community Ranking: | | 3.2 out of 5 ( ) |
| Outperform Votes: | | 177 (Thanks for Voting!) |
| Underperform Votes: | | 103 (Thanks for Voting!) |
| Total Votes: | | 280 |
ADMA Biologics (NASDAQ:ADMA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for ADMA Biologics in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 37.87%. The high price target for ADMA is $10.00 and the low price target for ADMA is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.50 | $6.50 | $6.50 | $9.00 |
| Price Target Upside: | 37.87% upside | 69.27% upside | 135.51% upside | 262.90% upside |
ADMA Biologics (NASDAQ:ADMA) Consensus Price Target History
ADMA Biologics (NASDAQ:ADMA) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/14/2018 | Maxim Group | Set Price Target | Buy | $10.00 | Medium |  |
| 11/14/2017 | Raymond James | Upgrade | Market Perform ➝ Outperform | $5.00 | N/A | |
(Data available from 5/21/2016 forward)
ADMA Biologics (NASDAQ:ADMA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ADMA Biologics (NASDAQ ADMA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 37.59%
ADMA Biologics (NASDAQ ADMA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/9/2017 | Adam S Grossman | Insider | Buy | 485,000 | $2.15 | $1,042,750.00 | | |
| 11/9/2017 | Brian Lenz | CFO | Buy | 6,500 | $2.15 | $13,975.00 | 15,000 | |
| 11/9/2017 | Eric I Richman | Director | Buy | 25,000 | $2.15 | $53,750.00 | 31,300 | |
| 11/9/2017 | James Mond | CMO | Buy | 10,000 | $2.15 | $21,500.00 | 13,389 | |
| 5/3/2016 | Adam S Grossman | CEO | Buy | 200,000 | $6.50 | $1,300,000.00 | | |
| 5/3/2016 | Brian Lenz | CFO | Buy | 2,500 | $6.50 | $16,250.00 | 8,500 | |
| 5/3/2016 | James Mond | CMO | Buy | 770 | $6.50 | $5,005.00 | 3,389 | |
| 5/3/2016 | Jerrold B Grossman | Director | Buy | 45,769 | $6.50 | $297,498.50 | | |
| 12/8/2015 | Adam S. Grossman | CEO | Buy | 500 | $9.00 | $4,500.00 | 637,268 | |
| 12/7/2015 | Jerrold B Grossman | Director | Buy | 500 | $9.01 | $4,505.00 | 56,558 | |
| 12/2/2015 | Adam S Grossman | CEO | Buy | 2,250 | $9.15 | $20,587.50 | 636,768 | |
| 12/2/2015 | Brian Lenz | CFO | Buy | 1,000 | $9.15 | $9,150.00 | 6,000 | |
| 12/2/2015 | Jerrold B Grossman | Director | Buy | 6,000 | $9.16 | $54,960.00 | 56,058 | |
| 12/1/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.17 | $16,506.00 | | |
| 11/25/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.18 | $16,524.00 | | |
| 11/20/2015 | Adam S Grossman | CEO | Buy | 3,861 | $9.21 | $35,559.81 | 628,418 | |
| 3/19/2015 | Adam S Grossman | CEO | Buy | 2,000 | $8.50 | $17,000.00 | | |
| 3/17/2015 | Adam S Grossman | CEO | Buy | 5,500 | $7.98 | $43,890.00 | | |
| 3/17/2015 | Jerrold B Grossman | Director | Buy | 500 | $8.01 | $4,005.00 | | |
| 3/16/2015 | Adam S Grossman | CEO | Buy | 8,800 | $8.03 | $70,664.00 | | |
| 3/16/2015 | James Mond | CMO | Buy | 1,250 | $8.02 | $10,025.00 | | |
| 3/16/2015 | Lawrence P Guiheen | Director | Buy | 1,000 | $7.96 | $7,960.00 | | |
| 3/13/2015 | Eric I Richman | Director | Buy | 3,500 | $7.88 | $27,580.00 | | |
| 9/12/2014 | Adam S Grossman | CEO | Buy | 4,300 | $9.57 | $41,151.00 | | |
| 8/22/2014 | Adam S Grossman | CEO | Buy | 1,000 | $9.50 | $9,500.00 | | |
| 8/14/2014 | Adam S Grossman | CEO | Buy | 2,100 | $9.77 | $20,517.00 | | |
| 6/18/2014 | Adam S Grossman | CEO | Buy | 1,875 | $9.59 | $17,981.25 | | |
| 5/22/2014 | Adam S Grossman | CEO | Buy | 4,226 | $8.15 | $34,441.90 | | |
| 5/15/2014 | Adam S Grossman | CEO | Buy | 13,400 | $7.50 | $100,500.00 | | |
| 5/14/2014 | Brian Lenz | CFO | Buy | 1,000 | $7.50 | $7,500.00 | | |
| 5/14/2014 | James Mond | CMO | Buy | 1,315 | $7.60 | $9,994.00 | | |
| 12/10/2013 | Jerrold B Grossman | Director | Buy | 3,650 | $7.30 | $26,645.00 | | |
(Data available from 1/1/2013 forward)
ADMA Biologics (NASDAQ ADMA) News Headlines
| Source: |
|
ADMA Biologics (NASDAQ:ADMA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ADMA Biologics (NASDAQ:ADMA) Income Statement, Balance Sheet and Cash Flow Statement
ADMA Biologics (NASDAQ ADMA) Stock Chart for Monday, May, 21, 2018
Loading chart…
